Compare Dr. Reddys with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs SANOFI INDIA - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB SANOFI INDIA DR. REDDYS LAB/
SANOFI INDIA
 
P/E (TTM) x 21.5 36.1 59.5% View Chart
P/BV x 3.2 6.3 50.8% View Chart
Dividend Yield % 0.7 1.4 53.3%  

Financials

 DR. REDDYS LAB   SANOFI INDIA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
SANOFI INDIA
Dec-18
DR. REDDYS LAB/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs2,8756,840 42.0%   
Low Rs1,8884,630 40.8%   
Sales per share (Unadj.) Rs930.21,203.1 77.3%  
Earnings per share (Unadj.) Rs117.4165.3 71.1%  
Cash flow per share (Unadj.) Rs185.8209.9 88.5%  
Dividends per share (Unadj.) Rs20.0084.00 23.8%  
Dividend yield (eoy) %0.81.5 57.3%  
Book value per share (Unadj.) Rs844.4963.6 87.6%  
Shares outstanding (eoy) m166.0723.03 721.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.64.8 53.7%   
Avg P/E ratio x20.334.7 58.4%  
P/CF ratio (eoy) x12.827.3 46.9%  
Price / Book Value ratio x2.86.0 47.4%  
Dividend payout %17.050.8 33.5%   
Avg Mkt Cap Rs m395,496132,078 299.4%   
No. of employees `00022.03.3 665.4%   
Total wages/salary Rs m33,5624,068 825.0%   
Avg. sales/employee Rs Th7,032.88,393.8 83.8%   
Avg. wages/employee Rs Th1,527.91,232.4 124.0%   
Avg. net profit/employee Rs Th887.71,153.0 77.0%   
INCOME DATA
Net Sales Rs m154,48227,708 557.5%  
Other income Rs m3,375897 376.3%   
Total revenues Rs m157,85728,605 551.9%   
Gross profit Rs m31,7826,235 509.7%  
Depreciation Rs m11,3481,027 1,105.0%   
Interest Rs m8897 12,700.0%   
Profit before tax Rs m22,9206,098 375.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,8582,292 168.3%   
Profit after tax Rs m19,5003,806 512.3%  
Gross profit margin %20.622.5 91.4%  
Effective tax rate %16.837.6 44.8%   
Net profit margin %12.613.7 91.9%  
BALANCE SHEET DATA
Current assets Rs m111,10115,922 697.8%   
Current liabilities Rs m58,9736,235 945.8%   
Net working cap to sales %33.735.0 96.5%  
Current ratio x1.92.6 73.8%  
Inventory Days Days7964 124.7%  
Debtors Days Days9421 451.4%  
Net fixed assets Rs m101,2457,539 1,342.9%   
Share capital Rs m830230 360.9%   
"Free" reserves Rs m139,40621,962 634.8%   
Net worth Rs m140,23622,192 631.9%   
Long term debt Rs m22,0000-   
Total assets Rs m224,65629,839 752.9%  
Interest coverage x26.8872.1 3.1%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.70.9 74.1%   
Return on assets %9.112.8 71.0%  
Return on equity %13.917.2 81.1%  
Return on capital %14.927.5 54.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m88,6737,587 1,168.7%   
Fx outflow Rs m19,1047,145 267.4%   
Net fx Rs m69,569442 15,739.6%   
CASH FLOW
From Operations Rs m28,7043,739 767.7%  
From Investments Rs m-7,727-731 1,057.0%  
From Financial Activity Rs m-21,326-1,972 1,081.4%  
Net Cashflow Rs m-3141,036 -30.3%  

Share Holding

Indian Promoters % 25.5 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 5.4 14.4 37.5%  
FIIs % 35.3 14.6 241.8%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 10.5 145.7%  
Shareholders   75,885 15,184 499.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   VENUS REMEDIES  ORCHID PHARMA LTD  GSK PHARMA  J.B.CHEMICALS  SHASUN PHARMA  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA 2017-18 Annual Report Analysis (Annual Result Update)

Apr 16, 2019 | Updated on Apr 16, 2019

Here's an analysis of the annual report of SANOFI INDIA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.

SANOFI INDIA Announces Quarterly Results (3QFY19); Net Profit Up 4.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, SANOFI INDIA has posted a net profit of Rs 793 m (up 4.3% YoY). Sales on the other hand came in at Rs 7 bn (up 8.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Oct 18, 2019 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS